<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103100</url>
  </required_header>
  <id_info>
    <org_study_id>F140903008</org_study_id>
    <nct_id>NCT03103100</nct_id>
  </id_info>
  <brief_title>Comparing Bupivacaine, Lidocaine, and a Combination of Bupivacaine and Lidocaine for Labor Epidural Activation</brief_title>
  <official_title>Comparing Bupivacaine, Lidocaine, and a Combination of Bupivacaine and Lidocaine for Labor Epidural Activation: A Prospective, Randomized, Double-Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare and determine the most ideal local anesthetic (LA) solution to&#xD;
      activate a labor epidural: lidocaine, bupivacaine, or a combination of bupivacaine plus&#xD;
      lidocaine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most common and effective method for controlling labor pains is a local anesthetic (LA)&#xD;
      infusion through a lumbar epidural. To achieve adequate pain control during the first stage&#xD;
      of labor - onset of contractions to complete cervical dilation - nerve fibers up to the T10&#xD;
      dermatome must be anesthetized. When a patient is in active labor and an epidural catheter is&#xD;
      placed, the anesthesiologist must activate the epidural by administering LA through the&#xD;
      epidural to promote spread of the LA in the epidural space to anesthetize the nerve fibers&#xD;
      involved in the conduction of labor pains. The ideal LA to achieve this goal is one that&#xD;
      would allow for the fastest onset to achieve quick pain relief with the fewest side effects.&#xD;
&#xD;
      Two commonly used LA to provide labor analgesia are bupivacaine and lidocaine. When low&#xD;
      concentrations - 0.25% bupivacaine and 1% lidocaine - are used for labor analgesia, both of&#xD;
      these LA can be administered safely with very little concern of major adverse effects&#xD;
      associated with LA toxicity. Given that there is limited and conflicting evidence for the&#xD;
      usefulness of the bupivacaine and lidocaine mixture especially as it relates to labor&#xD;
      epidural activation, we hope to readdress these questions in an effort to determine whether&#xD;
      or not the LA combination offers any distinct advantage over the individual LA. The&#xD;
      investigators intend to determine the time it takes to achieve an adequate level (T10) for&#xD;
      labor analgesia, the total spread of local anesthetic, and the degree of motor block as these&#xD;
      factors will be important in determining the most optimal LA solution to activate a labor&#xD;
      epidural. With the results from this study, the investigators hope to recommend a LA solution&#xD;
      that will allow for the fastest pain relief in the laboring mother with the fewest side&#xD;
      effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2015</start_date>
  <completion_date type="Actual">September 9, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Achieve an Adequate Epidural Level for Labor Analgesia</measure>
    <time_frame>Baseline to 1 hour</time_frame>
    <description>time it takes to achieve a T10 dermatome level by pinprick. A T10 dermatome level is what is needed to control labor pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Achieve Adequate Analgesia</measure>
    <time_frame>Baseline to 1 hour</time_frame>
    <description>The number of patients who received an adequate epidural level of T10 or higher</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Motor Block</measure>
    <time_frame>Baseline to 1 hour</time_frame>
    <description>degree of motor block which means the amount of weakness in the legs experienced by the participants. this was determined by using the Bromage scale where 4 = greatest amount of motor block or muscle weakness and 0 = the least amount of motor block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Experienced of Maternal Hypotension</measure>
    <time_frame>Baseline to 1 hour</time_frame>
    <description>Number of patients who experienced maternal hypotension defined as a blood pressure (BP) &gt;20% decline from baseline and need for vasopressor therapy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Labor Pain</condition>
  <arm_group>
    <arm_group_label>1% Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25% Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine plus Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Lidocaine</intervention_name>
    <description>10 mL of 1% lidocaine</description>
    <arm_group_label>1% Lidocaine</arm_group_label>
    <other_name>Lidoderm, Xylocaine, Recticare, Anecream,</other_name>
    <other_name>Solarcaine, Anestacon, Cutiecaine, Lidocoll,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.25% Bupivacaine</intervention_name>
    <description>10 mL of 0.25% bupivacaine</description>
    <arm_group_label>0.25% Bupivacaine</arm_group_label>
    <other_name>Marcaine and Sensorcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine plus Lidocaine</intervention_name>
    <description>5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine</description>
    <arm_group_label>Bupivacaine plus Lidocaine</arm_group_label>
    <other_name>Lidoderm, Xylocaine, Recticare, Anecream, Lmx4, Akten,</other_name>
    <other_name>Marcaine and Sensorcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant patients over the age of 19 who are scheduled for an induction of labor and&#xD;
             request an epidural are eligible for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt;19&#xD;
&#xD;
          -  allergy to the drug or drug class&#xD;
&#xD;
          -  preexisting neuropathy&#xD;
&#xD;
          -  history of back pain prior to pregnancy or history of back surgery&#xD;
&#xD;
          -  history of chronic opioid use&#xD;
&#xD;
          -  history of hypertension or hypertensive disorders of pregnancy&#xD;
&#xD;
          -  congenital or acquired cardiac disease&#xD;
&#xD;
          -  contraindication to epidural placement (patient refusal, severe coagulopathy,&#xD;
             infection at site of epidural needle insertion, severe hypovolemia)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy females admitted for induction of labor</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark F Powell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Department of Anesthesiology and Perioperative Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <results_first_submitted>July 17, 2020</results_first_submitted>
  <results_first_submitted_qc>August 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2020</results_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Mark Powell</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Local anesthetic</keyword>
  <keyword>Labor epidural</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labor Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03103100/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1% Lidocaine</title>
          <description>Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine&#xD;
1% Lidocaine: 10 mL of 1% lidocaine</description>
        </group>
        <group group_id="P2">
          <title>0.25% Bupivacaine</title>
          <description>Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine&#xD;
0.25% Bupivacaine: 10 mL of 0.25% bupivacaine</description>
        </group>
        <group group_id="P3">
          <title>Bupivacaine Plus Lidocaine</title>
          <description>Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.&#xD;
Bupivacaine plus Lidocaine: 5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1% Lidocaine</title>
          <description>Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine&#xD;
1% Lidocaine: 10 mL of 1% lidocaine</description>
        </group>
        <group group_id="B2">
          <title>0.25% Bupivacaine</title>
          <description>Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine&#xD;
0.25% Bupivacaine: 10 mL of 0.25% bupivacaine</description>
        </group>
        <group group_id="B3">
          <title>Bupivacaine Plus Lidocaine</title>
          <description>Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.&#xD;
Bupivacaine plus Lidocaine: 5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Achieve an Adequate Epidural Level for Labor Analgesia</title>
        <description>time it takes to achieve a T10 dermatome level by pinprick. A T10 dermatome level is what is needed to control labor pain.</description>
        <time_frame>Baseline to 1 hour</time_frame>
        <population>In the 1% lidocaine group, 1 participant experienced an adverse event and was removed from analysis and 1 participant was removed because they did not receive the study drug. In the bupivacaine plus lidocaine group 2 patients were removed because they did not receive the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Lidocaine</title>
            <description>Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine&#xD;
1% Lidocaine: 10 mL of 1% lidocaine</description>
          </group>
          <group group_id="O2">
            <title>0.25% Bupivacaine</title>
            <description>Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine&#xD;
0.25% Bupivacaine: 10 mL of 0.25% bupivacaine</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine Plus Lidocaine</title>
            <description>Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.&#xD;
Bupivacaine plus Lidocaine: 5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve an Adequate Epidural Level for Labor Analgesia</title>
          <description>time it takes to achieve a T10 dermatome level by pinprick. A T10 dermatome level is what is needed to control labor pain.</description>
          <population>In the 1% lidocaine group, 1 participant experienced an adverse event and was removed from analysis and 1 participant was removed because they did not receive the study drug. In the bupivacaine plus lidocaine group 2 patients were removed because they did not receive the study drug.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="3.9"/>
                    <measurement group_id="O2" value="11.0" spread="5.8"/>
                    <measurement group_id="O3" value="8.5" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Achieve Adequate Analgesia</title>
        <description>The number of patients who received an adequate epidural level of T10 or higher</description>
        <time_frame>Baseline to 1 hour</time_frame>
        <population>In the 1% lidocaine group, 1 participant experienced an adverse event and was removed from analysis and 1 participant was removed because they did not receive the study drug. In the bupivacaine plus lidocaine group 2 patients were removed because they did not receive the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Lidocaine</title>
            <description>Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine&#xD;
1% Lidocaine: 10 mL of 1% lidocaine</description>
          </group>
          <group group_id="O2">
            <title>0.25% Bupivacaine</title>
            <description>Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine&#xD;
0.25% Bupivacaine: 10 mL of 0.25% bupivacaine</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine Plus Lidocaine</title>
            <description>Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.&#xD;
Bupivacaine plus Lidocaine: 5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Achieve Adequate Analgesia</title>
          <description>The number of patients who received an adequate epidural level of T10 or higher</description>
          <population>In the 1% lidocaine group, 1 participant experienced an adverse event and was removed from analysis and 1 participant was removed because they did not receive the study drug. In the bupivacaine plus lidocaine group 2 patients were removed because they did not receive the study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Degree of Motor Block</title>
        <description>degree of motor block which means the amount of weakness in the legs experienced by the participants. this was determined by using the Bromage scale where 4 = greatest amount of motor block or muscle weakness and 0 = the least amount of motor block.</description>
        <time_frame>Baseline to 1 hour</time_frame>
        <population>In the 1% lidocaine group, 1 participant experienced an adverse event and was removed from analysis and 1 participant was removed because they did not receive the study drug. In the bupivacaine plus lidocaine group 2 patients were removed because they did not receive the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Lidocaine</title>
            <description>Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine&#xD;
1% Lidocaine: 10 mL of 1% lidocaine</description>
          </group>
          <group group_id="O2">
            <title>0.25% Bupivacaine</title>
            <description>Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine&#xD;
0.25% Bupivacaine: 10 mL of 0.25% bupivacaine</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine Plus Lidocaine</title>
            <description>Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.&#xD;
Bupivacaine plus Lidocaine: 5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of Motor Block</title>
          <description>degree of motor block which means the amount of weakness in the legs experienced by the participants. this was determined by using the Bromage scale where 4 = greatest amount of motor block or muscle weakness and 0 = the least amount of motor block.</description>
          <population>In the 1% lidocaine group, 1 participant experienced an adverse event and was removed from analysis and 1 participant was removed because they did not receive the study drug. In the bupivacaine plus lidocaine group 2 patients were removed because they did not receive the study drug.</population>
          <units>Bromage Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.6"/>
                    <measurement group_id="O2" value="1.7" spread="1.0"/>
                    <measurement group_id="O3" value="1.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Experienced of Maternal Hypotension</title>
        <description>Number of patients who experienced maternal hypotension defined as a blood pressure (BP) &gt;20% decline from baseline and need for vasopressor therapy</description>
        <time_frame>Baseline to 1 hour</time_frame>
        <population>In the 1% lidocaine group, 1 participant experienced an adverse event and was removed from analysis and 1 participant was removed because they did not receive the study drug. In the bupivacaine plus lidocaine group 2 patients were removed because they did not receive the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Lidocaine</title>
            <description>Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine&#xD;
1% Lidocaine: 10 mL of 1% lidocaine</description>
          </group>
          <group group_id="O2">
            <title>0.25% Bupivacaine</title>
            <description>Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine&#xD;
0.25% Bupivacaine: 10 mL of 0.25% bupivacaine</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine Plus Lidocaine</title>
            <description>Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.&#xD;
Bupivacaine plus Lidocaine: 5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Experienced of Maternal Hypotension</title>
          <description>Number of patients who experienced maternal hypotension defined as a blood pressure (BP) &gt;20% decline from baseline and need for vasopressor therapy</description>
          <population>In the 1% lidocaine group, 1 participant experienced an adverse event and was removed from analysis and 1 participant was removed because they did not receive the study drug. In the bupivacaine plus lidocaine group 2 patients were removed because they did not receive the study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of epidural placement until 1 hour after placement.</time_frame>
      <desc>In the 1% lidocaine group, 1 participant experienced an adverse event and was removed from analysis and 1 participant was removed because they did not receive the study drug. In the bupivacaine plus lidocaine group 2 patients were removed because they did not receive the study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>1% Lidocaine</title>
          <description>Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine&#xD;
1% Lidocaine: 10 mL of 1% lidocaine</description>
        </group>
        <group group_id="E2">
          <title>0.25% Bupivacaine</title>
          <description>Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine&#xD;
0.25% Bupivacaine: 10 mL of 0.25% bupivacaine</description>
        </group>
        <group group_id="E3">
          <title>Bupivacaine Plus Lidocaine</title>
          <description>Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.&#xD;
Bupivacaine plus Lidocaine: 5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark Powell</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-975-3328</phone>
      <email>mfpowell@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

